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Introduction {#cns12404-sec-0005}
============

Impaired insulin signaling is a physiological condition that cells lost the ability to respond to insulin. This failure to respond is called insulin resistance and plays a central in the development of the metabolic disorders such as diabetes, obesity, hypertension, and dyslipidemia. Particularly, defective brain insulin signaling has been implicated in the development of Alzheimer\'s disease (AD), the most common cause of dementia [1](#cns12404-bib-0001){ref-type="ref"}. In fact, abnormal insulin sensitivity is shown to be associated with AD‐related pathological features. For example, type 2 diabetes (T2D) is identified as a major risk factor for AD, suggesting defective insulin signaling may account for pathogenesis of neurodegeneration [2](#cns12404-bib-0002){ref-type="ref"}. Moreover, patients with AD show significantly reduced expression of insulin receptors and insulin receptor substrate (IRS) in the brain that contributes to the severity of cognitive impairment [3](#cns12404-bib-0003){ref-type="ref"}. All these findings suggest that neuronal insulin signaling is altered in the AD brain resembling T2D [4](#cns12404-bib-0004){ref-type="ref"}. Actually, AD pathogenesis is initially triggered by the presence of extracellular amyloid‐*β* (A*β*) proteins, which are found to cause oxidative stress and neurotoxicity in the brain [5](#cns12404-bib-0005){ref-type="ref"}. It is well known that insulin and its receptors are widely expressed in neurons and glial cells throughout the brain [6](#cns12404-bib-0006){ref-type="ref"}, and evidence is also presented that insulin can be produced locally within the brain [7](#cns12404-bib-0007){ref-type="ref"}. In addition, A*β* has been reported to impair synaptic insulin sensitivity in cultured neurons, which may impair synaptic functions associated with pathogenesis of AD [8](#cns12404-bib-0008){ref-type="ref"}. This indicates insulin signaling may serve as an important regulatory role in neurons. However, the molecular basis that links between insulin signaling and A*β*‐induced neurotoxicity remains unclear.

At a molecular level, the serine phosphorylation of insulin receptor substrate (IRS) can block the insulin signaling. This results in the inhibition of IRS tyrosine phosphorylation, suppressing the downstream phosphatidylinositol 3‐kinase (PI3‐kinase) signaling and subsequent inactivation of the kinase Akt [9](#cns12404-bib-0009){ref-type="ref"}. It is known that activated Akt inactivates glycogen synthase kinase 3*β* (GSK3*β*) by phosphorylating its Ser^9^ residue, which is one of the important enzymes induce tau hyperphosphorylation and neurotoxicity [10](#cns12404-bib-0010){ref-type="ref"}. For this reason, impairment of insulin signaling may result in a high activity of GSK3*β*, which leads to an enhanced tau hyperphosphorylation, a crucial step in AD pathogenesis. Hyperphosphorylated tau and A*β* cooperatively impair mitochondrial membrane potential and further increase in accumulation of intracellular reactive oxygen species (ROS), which ultimately result in neurodegeneration [11](#cns12404-bib-0011){ref-type="ref"}. Therefore, it is not surprising that pharmaceuticals found to be effective treatment of impaired insulin signaling have also shown benefits in the prevention or reduction of AD [12](#cns12404-bib-0012){ref-type="ref"}.

The enzyme dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous membrane‐bound prolyl peptidase that was responsible for the degradation of incretin hormones [13](#cns12404-bib-0013){ref-type="ref"}. Incretins are a group of gut‐derived hormones that potentiate insulin secretion and related cellular signaling [14](#cns12404-bib-0014){ref-type="ref"}. However, incretins are rapidly metabolized and inactivated by DPP‐4. As a result, DPP‐4 inhibitors such as linagliptin have a relevant effect of increasing the half‐life in retaining the physiological effects of endogenous incretins [15](#cns12404-bib-0015){ref-type="ref"}. Interestingly, it has been recently shown that incretins may be good candidates for treating AD [16](#cns12404-bib-0016){ref-type="ref"}. For example, glucagon‐like peptide‐1 (GLP‐1), the major incretin in humans, has been shown to elicit neuroprotective properties against AD pathological processes [17](#cns12404-bib-0017){ref-type="ref"}. Similar to insulin, GLP‐1 is produced in the brain mediating many neuronal functions, including neuroprotection, improvement of learning and memory ability, and potentiation of insulin signaling [18](#cns12404-bib-0018){ref-type="ref"}. Therefore, GLP‐1 signaling have demonstrated the potential to serve as therapeutic or preventive strategies against diabetes‐related AD [19](#cns12404-bib-0019){ref-type="ref"}. As DPP‐4 inhibitor effectively increases GLP‐1 levels, it may also exert protective effects against AD‐related A*β*‐induced neurotoxicity. Linagliptin is a recently approved DPP‐4 inhibitor and widely considered as the first‐line treatment for T2D patients. It has been demonstrated greater inhibitory effects than other DPP‐4 inhibitors such as alogliptin, saxagliptin, sitagliptin, or vildagliptin [20](#cns12404-bib-0020){ref-type="ref"}. Moreover, linagliptin also significantly improves insulin secretory dysfunction and sensitivity in animal studies [21](#cns12404-bib-0021){ref-type="ref"}. This indicates linagliptin may have beneficial effects on impaired insulin signaling in neuronal cells. However, whether linagliptin is involved in A*β*‐induced neurotoxicity is still largely unknown. In this study, we postulated that neuronal insulin resistance may be one of the underlying neurotoxic mechanisms by A*β*, whereas linagliptin can protect neuronal cells by restoring impaired insulin signaling, and thereby contribute to the alleviation of A*β*‐induced neurotoxicity.

Materials and Methods {#cns12404-sec-0006}
=====================

Materials {#cns12404-sec-0007}
---------

Chemicals such as 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT), 4′,6‐diamidino‐2‐phenylindole (DAPI), and JC‐1 were purchased from Sigma (München, Germany). Amyloid‐*β* (A*β*) 1‐42 was acquired from AnaSpec Inc. (San Jose, CA, USA). We purchased antibodies against Akt, p‐Akt, GSK3*β*, p‐GSK3*β* and IRS‐1, caspase 3, SOD1, and poly(ADP‐ribose) polymerase (PARP) from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Sirt1 antibody from GeneTex (Irvine, CA, USA), *β*‐actin antibody from Novus Biologicals (Littleton, CO, USA), and p‐IRS‐1 antibodies from Cell Signaling Technology (Danvers, MA, USA). Primary antibodies were used at a dilution of 1:1000 in 0.1% Tween‐20 and secondary antibodies were used at 1:5000 dilutions. Pure linagliptin was provided by Boehringer Ingelheim Pharmaceuticals (Biberach, Germany). All the chemicals were prepared by dissolving phosphate buffer saline solutions stored at −20°C until needed for use in experiments.

Cell Culture and Viability Assay {#cns12404-sec-0008}
--------------------------------

Human neuroblastoma SK‐N‐MC cells were obtained from the American Type Culture Collection (Bethesda, MD, USA). Cells were maintained in minimal Eagle\'s medium (MEM; Gibco, Carlsbad, CA, USA), supplemented with 10% fetal calf serum, 100 units/mL penicillin, 100 μg/mL streptomycin, and 2 mM L‐glutamine at 37°C, 5% CO~2~. The A*β* solutions were prepared as described previously [22](#cns12404-bib-0022){ref-type="ref"}. Briefly, A*β* ~1‐42~ lyophilizates were dissolved at 10 mM in 10% 60 mM NaOH and 90% 10 mM phosphate buffer (pH 7.4) as a stock reagent, and stored at −78°C until use. For viability assay, cells were seeded in 96‐welled plates at a density of 1 × 10^4^ cells/well overnight and then treated as indicated. After 24 h, the tetrazolium salt MTT was added to the medium following the manufacturer\'s instructions. Only viable cells could metabolize MTT into a purple formazan product, of which the color density (OD) was further quantified by an EZ Read 400 microplate reader (Biochrom, Holliston, MA, USA) at 550 nm. Cell viability was determined by the percentage of OD of the treated cells divided that of the untreated controls.

mRNA Expression Analysis by Reverse Transcription Quantitative PCR {#cns12404-sec-0009}
------------------------------------------------------------------

Total mRNA was extracted from the samples after treatment for the indicated conditions by utilizing the kit Qiagen RNeasy Kit (Qiagen, Germantown, MD, USA), and was quantified spectrophotometrically. RNA reverse transcription was performed at 25°C for 10 m for primer binding, 37°C for 120 min for reverse transcriptase, and 85°C for reverse transcriptase denaturation using the TProfessional Thermocycler (Biometra). Real‐time quantitative PCR (qPCR) was performed for quantification of mRNA by using an ABI 7300 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). PCR amplifications of target mRNA genes were carried out in conjunction with Power SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer\'s instructions. Each cDNA sample was tested in triplicate. The following temperature parameters were 95°C/10 min, 40 cycles of 95°C/15 s, 60°C/1 min and dissociation stage was 95°C/15 s, 60°C/15 s and 95°C/15 s. The following primer pairs were used, forward 5′‐ACACCTGTGCGGCTCACA‐3′ and reverse 5′‐TCCCGGCGGGTCTTG‐3′ for insulin, forward 5′‐TGCTTCCGGAGCTGTGATCT‐3′ and reverse 5′‐ CGGACAGAGCGAGCTGACTT‐3′ for IGF‐1, forward 5′‐ ATTGCTTGGCTGGTGAAAGG‐3′ and reverse 5′‐ TGTCTGCGGCCAAGTTCTTC‐3′ for proglucagon, and forward 5′‐TGGTATCGTGGAAGGACTCATGAC‐3′ and reverse 5′‐ATGCCAGTGAGCTTCCCGTTCAGC‐3′ for GAPDH. Values of relative mRNA expression were obtained by using the software SDS (Sequence Detection Systems 7300 Real Time PCR System; Applied Biosystems), and the values were standardized by comparing with values from relative expression of GAPDH.

Western Blot Analysis {#cns12404-sec-0010}
---------------------

After treatment, cells were harvested and homogenized in a protein extraction lysis buffer (50 mM Tris‐HCl, pH 8.0; 5 mM EDTA; 150 mM NaCl; 0.5% Nonidet P‐40; 0.5 mM phenylmethylsulfonyl fluoride; and 0.5 mM dithiothreitol), and centrifuged at 12,000 g for 30 min at 4°C. The supernatants were used as cell extracts for immunoblotting analysis. SDS‐solubilized samples were then loaded onto SDS‐polyacrylamide gels. Equal protein amounts of total cell lysates were resolved by 10% SDS‐PAGE, transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA), and then probed with a primary antibody followed by a secondary antibody conjugated with horseradish peroxidase. The immunocomplexes were visualized with enhanced chemiluminescence kits (Millipore). The relative expression of proteins was quantified densitometrically by using the software QuantityOne (BioRad, Hercules, CA, USA) and was calculated according to the reference bands of *β*‐actin. Each blot represents at least in three independent experiments.

Microscopic Observation and Nucleus Morphology {#cns12404-sec-0011}
----------------------------------------------

Changes in cell nucleus morphology, characteristic of apoptosis, were examined in cells grown on coverslips, using a microscope. The cells were fixed in 4% paraformaldehyde after 24 h of treatment with the indicated compounds. For phase‐contrast inverted microscopy, images of cells were captured with no specific staining procedure. For nucleus morphology microscopy, cells were fixed in ice‐cold methanol, and incubated for 15 min at room temperature with 1 ng/mL of 4′,6‐diamidino‐2‐phenylindole (DAPI) stain, and observed under a fluorescence microscope (DP80/BX53; Olympus, Tokyo, Japan). Apoptosis was quantified by averaging cell counts in twenty random 400× fields. Values were expressed as the percentage of apoptotic cells relative to total number of cells.

Measurement of Reactive Oxygen Species {#cns12404-sec-0012}
--------------------------------------

To evaluate the levels of intracellular ROS, cells were seeded onto glass coverslips and incubated with 10 μM of 2′, 7′‐dichlorodihydrofluorescin diacetate (DCFH‐DA, a general oxidative stress indicator) for 0.5 h at 37°C under 5% CO~2~ after treatment. After incubation, the staining medium was discarded and cells were washed twice with immediately with PBS, after which the intensity of fluorescence was imaged by a fluorescence microscopy (DP72/CKX41; Olympus) using an excitation wavelength of 488 nm and an emission wavelength of 525 nm. One representative image of three different experiments is shown.

Analysis of Mitochondrial Membrane Potential {#cns12404-sec-0013}
--------------------------------------------

The vital mitochondrial cationic dye JC‐1, which exhibits potential‐dependent accumulation in mitochondria, was used to investigate mitochondrial function. Cells were treated in fresh medium containing 1 μM JC‐1 and were incubated at 37°C for 30 min. The staining medium was then discarded and the cells were washed. Cells then imaged using an inverted fluorescence microscope (DP72/CKX41; Olympus) excited at 488 nm. In normal cells, JC‐1 continues to exist as aggregates and produces a red fluorescence (\~590 nm). During the induction of apoptosis, the mitochondrial potential collapses and JC‐1 forms a monomer producing green fluorescence (\~525 nm).

Blood Samples from Patients {#cns12404-sec-0014}
---------------------------

A total of 14 Chinese patients with non‐diabetic AD or diabetic AD were recruited from Chung Shan Medical University Hospital, Taichung, Taiwan. T2D was diagnosed according to the 1985 World Health Organization criteria using diagnostic values of fasting plasma glucose ≥7.0 mmol/L, and/or 2 h plasma glucose ≥11.1 mmol/L with or without 75 g oral glucose tolerance test, depending on the presence or absence of symptoms. AD was diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders IV (DSM‐IV) criteria. From each subject, 20 mL of venous peripheral ethylenediamine tetra‐acetic acid (EDTA) blood was obtained, and total RNA was isolated by utilizing the kit Qiagen RNeasy Kit (Qiagen) which was quantified spectrophotometrically in accordance with the manufacturer\'s instructions. The aforementioned protocol was approved by the Chung Shan Medical University Hospital Institutional Review Board (IRB) protocols (CSMUH No: CS13233). Informed consent was obtained from all participants according to the Declaration of Helsinki and was approved by the IRB.

Statistical Analysis {#cns12404-sec-0015}
--------------------

All data are presented as means ± standard error of the means (SEM). Statistical analysis of data was performed using analysis of variance (ANOVA), followed by Dunnett\'s post hoc test for multiple comparisons with SPSS statistical software (SPSS, Inc., Chicago, IL, USA). Differences were considered statistically significant at *P *\<* *0.05.

Results {#cns12404-sec-0016}
=======

Effects of Linagliptin on Viability of SK‐N‐MC Neuronal Cells {#cns12404-sec-0017}
-------------------------------------------------------------

The influence of DPP‐4 inhibitor linagliptin treated in neuronal cells is largely unknown. To evaluate the effects of linagliptin on cell viability, SK‐N‐MC neuronal cells were exposed to 10 to 100 μM of linagliptin for 24 h, and the cytotoxic effects were determined by MTT assay (Figure [1](#cns12404-fig-0001){ref-type="fig"}A). The results showed that linagliptin concentrations ranging from 10 to 50 μM did not induce significant cytotoxicity, whereas treatment with 100 μM linagliptin slightly reduced cell viability. In accordance, treated with 50 μM of linagliptin displays no significant time‐dependent change within a 48‐h period (Figure [1](#cns12404-fig-0001){ref-type="fig"}B). This indicates no detectable toxic effect is present at a concentration \<50 μM of linagliptin. Thus, in subsequent experiments, we investigated the mode of action of linagliptin at a concentration of 50 μM. It is known that the main action of linagliptin is to stimulate insulin action by the incretin hormones such as glucagon‐like peptide 1 (GLP‐1). To determine the effects of linagliptin on insulin signaling‐related gene expression in SK‐N‐MC cells, we performed relative expression qPCR assays to measure levels of mRNA transcripts. As shown in Figure [1](#cns12404-fig-0001){ref-type="fig"}C, adding linagliptin to SK‐N‐MC cells resulted in upregulation of insulin and insulin‐like growth factor‐1 (IGF‐1) but no significant effects in proglucagon (the pro‐hormonal precursor mRNA of GLP‐1), indicating linagliptin may exert its pharmacological action by stimulating insulin/IGF‐related signaling to neuronal cells.

![Effects of linagliptin on cell viability and incretin‐related mRNA expression in SK‐N‐MC neuronal cells. (**A**) Dose effects of linagliptin on SK‐N‐MC cells by MTT assay. Linagliptin shows no significant cytotoxicity \<50 μM. (**B**) 50 μM of linagliptin causes no significant alteration of cell viability within a 48‐h period. (**C**) SK‐N‐MC cells are treated with or without 50 μM of linagliptin for 24 h. The mRNA levels of incretin‐related target genes including insulin, insulin‐like growth factor‐1 (IGF‐1), and glucagon‐like peptide 1 (GLP‐1) are measured by using real‐time qPCR, and the results are presented as means ± standard error of the means (SEM) of three independent experiments. \**P *\<* *0.05 and \*\**P *\<* *0.01 by using multiple comparisons of Dunnett\'s post‐hoc test. N. S., no significant difference.](CNS-21-549-g001){#cns12404-fig-0001}

Linagliptin Protects SK‐N‐MC Cells Against A*β*‐induced Neurotoxicity {#cns12404-sec-0018}
---------------------------------------------------------------------

Recent studies have demonstrated the DPP‐4 inhibitory properties indicating neuroprotective effects against AD pathological hallmarks such as A*β* accumulation, tau phosphorylation and neuroinflammation [23](#cns12404-bib-0023){ref-type="ref"}. To assess whether linagliptin exerts these similar beneficial effects, cell viability assay was conducted to determine the neuroprotective effect of linagliptin on A*β*‐induced cell death. As shown in Figure [2](#cns12404-fig-0002){ref-type="fig"}A, incubation of SK‐N‐MC cells with 2.5 μM of A*β* for 24 h markedly underwent a \~50% decrease of MTT reduction. However, linagliptin alleviated cell death at concentrations ranging from 10 to 50 μM of SK‐N‐MC cells in a dose‐dependent manner during A*β* treatment. To precisely determine which mode of cell death is induced by A*β*, we examined the expressions of cleaved caspase 3 and poly (ADP‐ribose) polymerase (PARP), two typical markers of apoptosis by western blotting. As shown in Figure [2](#cns12404-fig-0002){ref-type="fig"}B, A*β* markedly increased cleavage of caspase 3 and PARP, indicating the enhanced apoptosis occurs mainly in A*β* treatment. On the contrary, co‐treated with linagliptin was shown to effectively inhibit caspase 3 and PARP activation by A*β*. These results were also confirmed by DAPI staining that treatment with linagliptin significantly reduced nuclei fragmentation as shown in Figure [2](#cns12404-fig-0002){ref-type="fig"}C. Taken together, this support the idea that the addition of linagliptin may effectively attenuate A*β*‐induced apoptosis in neuronal cells.

![Linagliptin protects against A*β*‐induced SK‐N‐MC cell death. (**A**) MTT assays indicate 2.5 μM of A*β* markedly induces cell death after 24 h of incubation. However, linagliptin significantly prevents A*β*‐induced neurotoxic effects in a dose‐dependent manner. (**B**) Western blotting results demonstrate that linagliptin (50 μM) treatment suppresses both caspase 3 and PARP activation induced by A*β* (2.5 μM). (**C**) Linagliptin (50 μM) markedly reduces 2.5 μM of A*β*‐induced nucleus fragmentation. Apoptosis is determined by fragmented morphology in the nucleus for DAPI fluorescence. The numbers of apoptotic cells are quantified by averaging cell counts in twenty random 400× fields. Other data were performed in three independent experiments, and values are presented as mean ± SEM. Significant differences was determined by using the multiple comparisons of Dunnett\'s post‐hoc test for \**P *\<* *0.05 and \*\**P *\<* *0.01 compared to A*β* only groups. Scale bar represents 50 μm.](CNS-21-549-g002){#cns12404-fig-0002}

Linagliptin Restores A*β*‐induced Insulin Signaling Blockade in Neuronal Cells {#cns12404-sec-0019}
------------------------------------------------------------------------------

Because the mechanism of DPP‐4 inhibitors is to increase endogenous incretin levels, we proposed that linagliptin might exert neuroprotective effects by enhancing GLP‐1 downstream signaling. To determine whether linagliptin‐mediated neuroprotection operates via alteration of GLP‐1 receptor expression in the SK‐N‐MC cells, we performed immunocytochemical staining. As shown in Figure [3](#cns12404-fig-0003){ref-type="fig"}A, both A*β* and linagliptin treatment did not markedly alter the cellular distribution and expression of GLP‐1 receptor in SK‐N‐MC cells. Similarly, the constant expression of GLP‐1 receptor was also confirmed by western blotting (Figure [3](#cns12404-fig-0003){ref-type="fig"}B). Several lines of evidence have indicated that linagliptin can enhance insulin action and plays an important role in improving insulin sensitivity in peripheral tissues [24](#cns12404-bib-0024){ref-type="ref"}. To further elucidate the molecular mechanism of linagliptin‐mediated neuroprotection, Western blot analysis was conducted to detect the levels of phospho insulin receptor substrate‐1 (IRS‐1) at residue Ser^307^ and Tyr in SK‐N‐MC cells. As shown in Figure [3](#cns12404-fig-0003){ref-type="fig"}C, A*β* treatment for 24 h caused a significant increase in Ser^307^ IRS‐1 phosphorylation, which is recognized as a hallmark of insulin resistance. Accordingly, A*β* also prevented IRS‐1 phosphotyrosine (4G10 clone) expression. By contrast, co‐treated with linagliptin returned the Tyr phosphorylation of IRS‐1 and its downstream target Akt to basal levels, showing that the neuronal insulin signaling can be activated by linagliptin during A*β* treatment. To gain insight into the downstream effects of Akt in the presence of linagliptin, we investigated the glycogen synthase kinase 3*β* (GSK3*β*), a direct phosphorylation target of Akt. After 24 h of A*β* treatment, the Ser^9^ phosphorylation of GSK3*β* was markedly inhibited, which indicates the A*β*‐suppressed Akt pathway leads to activation of GSK3*β* (Figure [3](#cns12404-fig-0003){ref-type="fig"}D). However, linagliptin could reduce GSK3*β* activity by increasing Akt‐mediated GSK3*β* Ser^9^ phosphorylation during A*β* treatment. This linagliptin‐mediated neuroprotection was also confirmed by inhibiting Thr^231^ phosphorylation of one GSK3*β*\'s downstream substrate tau, which was recognized as one of the crucial pathological hallmarks of AD. To further investigate the role of insulin signaling in linagliptin‐mediated neuroprotection, the PI3‐kinase inhibitor LY294002 was used as negative control. As shown is Figure [3](#cns12404-fig-0003){ref-type="fig"}D and [3](#cns12404-fig-0003){ref-type="fig"}E, LY294002 significantly blocked the linagliptin‐restored Akt signaling and cell viability during A*β* treatment. This indicates that A*β*‐impaired insulin signaling may trigger neuronal apoptosis; however, linagliptin effectively reduces A*β*‐induced cytotoxicity by returning the blocked neuronal insulin signaling.

![Linagliptin alleviates A*β*‐impaired insulin downstream signaling in SK‐N‐MC neuronal cells. (**A**) Immunofluorescence images show that the cellular distribution of GLP‐1 receptor is not altered by treatment with A*β* (2.5 μM), linagliptin (50 μM) or in combination for 24 h. (**B**) Western blotting also reveals that the expression of GLP‐1 receptor is not altered by A*β* (2.5 μM) or linagliptin (50 μM) treatment for 24 h in SK‐N‐MC cells. (**C**) Immunoblotting reveals that phosphorylation of Tyr‐IRS‐1 and Ser^473^‐Akt are inhibited when cells are exposed to A*β* (2.5 μM) for 24 h, and this inhibition is effectively restored by linagliptin (50 μM). (**D**) Western blotting shows that 50 μM of linagliptin‐activated Akt leads to the Ser^9^ phosphorylation of GSK3*β*, resulting in the inhibition of tau Thr^231^ phosphorylation by A*β* (2.5 μM) for 24 h. (**E**) Cell viability is determined by MTT assay, and the linagliptin‐mediated neuroprotective effects are abolished by the co‐treatment of LY294002 (20 μM), a specific inhibitor of PI3‐kinase. All data were performed in three independent experiments, and values are presented as mean ± SEM. Significant differences was determined by using the multiple comparisons of Dunnett\'s post‐hoc test for \**P *\<* *0.05 and \*\**P *\<* *0.01. Scale bar represents 20 μm.](CNS-21-549-g003){#cns12404-fig-0003}

Linagliptin Protects Cells Against A*β*‐Induced Intracellular ROS Accumulation and Mitochondria Dysfunction {#cns12404-sec-0020}
-----------------------------------------------------------------------------------------------------------

Previous studies show strong evidence that A*β*‐induced ROS accumulation and mitochondrial dysfunction are both potential pathogenic markers in AD [25](#cns12404-bib-0025){ref-type="ref"}. To determine whether linagliptin protects cells from A*β*‐induced oxidative stress, we measured intracellular ROS levels by a 2′,7′‐dichlorofluorescin diacetate (DCFH‐DA) fluorometric method. As expected, our results showed that linagliptin suppresses A*β*‐induced ROS intracellular accumulation, which in turn protects cells from oxidative stress (Figure [4](#cns12404-fig-0004){ref-type="fig"}A). It is also suggested that increased ROS levels may inhibit AMP‐activated protein kinase (AMPK) activity, which is likely to promote the development of insulin resistance [26](#cns12404-bib-0026){ref-type="ref"}. To test whether such mechanism is also involved in SK‐N‐MC cells, the phosphorylation of AMPK was determined by immunoblotting in Figure [4](#cns12404-fig-0004){ref-type="fig"}B. Our results showed that A*β* significantly downregulates the Thr^172^ phosphorylation of AMPK, whereas this effect was counteracted by co‐treatment of linagliptin. Furthermore, western blot analysis of AMPK downstream target sirtuin 1 (Sirt1) and superoxide dismutase 1 (SOD1) protein expressions also provided evidence that levels of these antioxidative pathways are increased significantly by linagliptin compared to A*β* only groups. As discussed previously, the pathogenic role of A*β* in mediating ROS accumulation was often accompanied by mitochondrial dysfunction. To further examine the details of linagliptin‐mediated neuroprotection, we performed JC‐1 staining to assess the mitochondrial membrane potential. As shown in Figure [4](#cns12404-fig-0004){ref-type="fig"}C, JC‐1 aggregates were found in healthy mitochondria by a red fluorescence in nontreated controls. However, exposure of cells to A*β* resulted in significant increases in green fluorescence, indicating a loss of mitochondrial membrane potential. On the contrary, co‐treatment with linagliptin reduced the deteriorating effects of A*β* on mitochondrial membrane potential. We further confirmed that insulin signaling inhibition results in an oxidative stress damage by A*β*, as the PI3‐kinase inhibitor LY294002 significantly attenuated linagliptin‐mediated antioxidative effects, suggesting these benefits may depend on linagliptin‐improved insulin sensitivity in neuronal cells.

![Linagliptin reduces A*β*‐induced intracellular ROS accumulation and improves mitochondria dysfunction. (**A**) Effects of linagliptin (50 μM) in reducing 2.5 μM of A*β*‐induced intracellular ROS accumulation determined by dichlorofluorescin diacetate (DCFH‐DA) staining under microscope. (**B**) Effects of linagliptin (50 μM), A*β* (2.5 μM), and LY294002 (20 μM) on Thr^172^ phosphorylation of AMPK, and the protein levels of AMPK, Sirt1 and SOD1 by immunoblotting. (**C**) JC‐1 immunofluorescent staining. Green fluorescence represents A*β*‐induced mitochondrial dysfunction by dissipation of mitochondrial membrane potential. Red fluorescence indicates that co‐treatment with linagliptin (50 μM) preserved an intact mitochondrial membrane potential compared with the group treated with A*β* (2.5 μM) alone. LY294002 (20 μM), a specific inhibitor of PI3‐kinase. Scale bar represents 20 μm.](CNS-21-549-g004){#cns12404-fig-0004}

Peripheral Blood Leukocyte Sirt1 mRNA Expression is Partially Returned by Linagliptin in Diabetic Patients with AD {#cns12404-sec-0021}
------------------------------------------------------------------------------------------------------------------

Sirt1 is an important modulator in humans in the protection against oxidative events. A previous study reported that the Sirt1 mRNA expression level is suppressed in blood samples obtained from patients with AD or T2D [27](#cns12404-bib-0027){ref-type="ref"}, [28](#cns12404-bib-0028){ref-type="ref"}. However, it remains unclear whether the reduction of Sirt1 mRNA is more susceptible to diabetic patients with AD. To evaluate Sirt1 inhibition in diabetic AD patients, peripheral leukocytes were isolated and Sirt1 mRNA levels were determined with fourteen human subjects with clinically diagnosed AD (six pure AD, four diabetic AD without linagliptin treatments, and four diabetic AD with linagliptin treatments at least for 6 months). A detailed overview of the patient\'s characteristics is summarized in Table [1](#cns12404-tbl-0001){ref-type="table"}. In line with our preliminary expectation, both mini‐mental state examination (MMSE) scores and Sirt1 mRNA expressions were lower in patients with diabetic AD as compared to pure patients with AD. However, the MMSE scores and expressions of Sirt1 mRNA were significantly restored in diabetic patients with AD treated with linagliptin (Table [1](#cns12404-tbl-0001){ref-type="table"}). This observation consists the idea that patients with diabetic AD expressed reduced Sirt1 by inhibition of incretin signaling, which may contribute to pathogenesis of neurodegeneration.

###### 

Characteristics of patients with AD, and diabetic AD treated with or without linagliptin

  Characteristics      Non‐diabetic AD (n = 6)                             Diabetic AD no linagliptin (n = 4)   Diabetic AD treated with linagliptin (n = 4)
  -------------------- --------------------------------------------------- ------------------------------------ ----------------------------------------------------
  Age, years           81.3 ± 5.4                                          83.5 ± 4.5                           79.5 ± 3.4
  Sex (male/female)    3/3                                                 2/2                                  2/2
  MMSE score           20.6 ± 2.0[a](#cns12404-note-0004){ref-type="fn"}   15.5 ± 3.4                           20.3 ± 4.1
  Sirt1 mRNA (folds)   2.6 ± 0.66[a](#cns12404-note-0004){ref-type="fn"}   1.0 ± 0.29                           1.88 ± 0.28[a](#cns12404-note-0004){ref-type="fn"}

AD, Alzheimer\'s disease; MMSE, mini‐mental status examination.

Values shown are means ± SD.

*P *\<* *0.05 compared to diabetic AD groups.
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Discussion {#cns12404-sec-0022}
==========

Interestingly, accumulating evidence indicates a strong link between T2D and AD, highlighting the key role of insulin signaling in the pathogenesis of these diseases. Although the underlying mechanism remains largely unknown, now the evidence for it has become very significant [29](#cns12404-bib-0029){ref-type="ref"}. In fact, Steen *et al*. have firstly proposed a connection between increased insulin resistance in the brain with AD and termed it as "type 3 diabetes" [30](#cns12404-bib-0030){ref-type="ref"}, hinting that insulin‐based therapies may be useful in the treatment of AD. Traditionally, the majority of insulin in the brain is generated from pancreatic *β*‐cells and transported across the blood--brain barrier (BBB). However, insulin can be locally synthesized and released by neurons [31](#cns12404-bib-0031){ref-type="ref"}. Moreover, GLP‐1 and its receptor are also known to ubiquitously express in central nervous system (CNS), particularly in hypothalamus, cortex and hippocampus that typically vulnerable in patients with AD [32](#cns12404-bib-0032){ref-type="ref"}. Therefore, it is not surprising that the locally produced GLP‐1 may be upregulated by treatment with a DPP‐4 inhibitor which stimulates insulin downstream effects related to neuronal functions. Regarding the insulin protective effects in CNS, we provided evidence that linagliptin can protect neuronal cells against A*β*‐induced neurotoxicity likely by blocking DPP‐4 makes GLP‐1 levels rise, which increases insulin release and restores insulin signaling impairment. As brain GLP‐1 has been suggested to be neuroprotective [33](#cns12404-bib-0033){ref-type="ref"}, it is possible that DPP‐4 inhibitors such as linagliptin may represent a promising strategy against A*β*‐induced neurodegeneration.

Insulin resistance and mitochondrial dysfunction are the two common features both in AD and T2D [34](#cns12404-bib-0034){ref-type="ref"}. As previous mentioned, mitochondrial dysfunction leads to impairment of insulin sensitivity by reduced activity of AMPK, an important cellular fuel sensor and regulator [35](#cns12404-bib-0035){ref-type="ref"}. A*β* was found to cause ROS accumulation and oxidative damage in the brain, which is believed to play a pivotal role in the development of insulin resistance [36](#cns12404-bib-0036){ref-type="ref"}. Interestingly, GLP‐1 has been reported to stimulate AMPK activation in preventing the ROS production and *vice versa* [37](#cns12404-bib-0037){ref-type="ref"}. Additionally, AMPK activation has also been suggested to enhance insulin sensitivity by GLP‐1 agonist liraglutide [38](#cns12404-bib-0038){ref-type="ref"}. This indicates that AMPK may play a key role in response to A*β* exposure by DPP‐4 inhibition. In accordance with these findings, we found that the Thr^172^ phosphorylation of AMPK could be reduced during the incubation of cells with A*β*, and this inhibition was prevented by linagliptin co‐treatment. Moreover, we also observed that linagliptin protects mitochondrial function and suppresses intracellular ROS accumulation depends on insulin signaling pathways. These observations were further confirmed by Sirt1, a well‐known longevity factor, is in fact upregulated by linagliptin. By linagliptin treatment, AMPK can trigger its downstream target Sirt1, which was reported previously in triggering antioxidant pathways such as SOD [39](#cns12404-bib-0039){ref-type="ref"}. Considering the important roles of the A*β*‐induced oxidative stress in AD pathogenesis, our research unveils a new neuroprotective mechanism by which linagliptin suppresses oxidative damage and preserves mitochondria function through restoration of neuronal insulin signaling.

Recently, Kosaraju *et al*. [40](#cns12404-bib-0040){ref-type="ref"}, [41](#cns12404-bib-0041){ref-type="ref"} observed that inhibition of DPP‐4 ameliorates streptozotocin‐induced memory loss and neuronal death in rats, indicating the possibility of using of these agents for the treating diabetes‐associated AD. Their results revealed a significant improvement in a dose‐dependent attenuation of A*β* production, tau hyperphosphorylation and cognitive deficits by upregulation of GLP‐1 signaling. These robust therapeutic effects of DPP‐4 inhibitors demonstrate a unique mechanism for A*β*‐related pathology observed in AD. However, previous study has demonstrated that linagliptin does not pass through the BBB easily [42](#cns12404-bib-0042){ref-type="ref"}, whereas GLP‐1 could be able to effectively penetrate into the brain [43](#cns12404-bib-0043){ref-type="ref"}. Because linagliptin has been suggested to have direct neuroprotective effects, we postulate that linagliptin treatment may increase levels of brain blood GLP‐1 and confers its neuroprotection. This is further supported by the fact that linagliptin‐mediated neuroprotection occurs directly at the neuronal level because the brain expression of GLP‐1 receptors is exclusively in neurons [44](#cns12404-bib-0044){ref-type="ref"}. However, further evaluation is necessary to confirm the neuroprotective effect of linagliptin in patients with AD. Collectively, in the present study we provided evidence for the view that linagliptin inhibits neurotoxicity induced by A*β*. This protection appears to be associated with the insulin signaling‐dependent AMPK activation and the Sirt1‐elicited antioxidant pathways such as SOD1. To our knowledge, this is the first report demonstrating the AMPK‐Sirt1 molecular mechanism of linagliptin against A*β*‐induced insulin signaling impairment and oxidative damage. Our report therefore provides new insights that incretin‐based agents such as linagliptin may be a potential useful therapeutic approach to AD.
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